Aquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting

Reuters

10/30

Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting

Aquestive Therapeutics Inc. has announced that multiple presentations related to its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, taking place November 6-10, 2025, in Orlando, FL. The presentations will include an oral session on Phase 1 evaluation of sublingual film pharmacokinetics, pharmacodynamics, safety, and tolerability in at-risk pediatric patients, as well as poster presentations on pharmacokinetics in adult and pediatric subjects and insights from clinician and caregiver surveys regarding unmet needs in anaphylaxis care. The results are scheduled to be presented at the ACAAI Annual Meeting, and abstracts will be made available online beginning November 6, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564886-en) on October 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579811787"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579811787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579811787?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579811787","market":"fut","top_or_hot":-1,"title":"Aquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AQST\">Aquestive Therapeutics Inc.</a> has announced that multiple presentations related to its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, taking place November 6-10, 2025, in Orlando, FL. The presentations will include an oral session on Phase 1 evaluation of sublingual film pharmacokinetics, pharmacodynamics, safety, and tolerability in at-risk pediatric patients, as well as poster presentations on pharmacokinetics in adult and pediatric subjects and insights from clinician and caregiver surveys regarding unmet needs in anaphylaxis care. The results are scheduled to be presented at the ACAAI Annual Meeting, and abstracts will be made available online beginning November 6, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564886-en) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-30 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AQST\">Aquestive Therapeutics Inc.</a> has announced that multiple presentations related to its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, taking place November 6-10, 2025, in Orlando, FL. The presentations will include an oral session on Phase 1 evaluation of sublingual film pharmacokinetics, pharmacodynamics, safety, and tolerability in at-risk pediatric patients, as well as poster presentations on pharmacokinetics in adult and pediatric subjects and insights from clinician and caregiver surveys regarding unmet needs in anaphylaxis care. The results are scheduled to be presented at the ACAAI Annual Meeting, and abstracts will be made available online beginning November 6, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564886-en) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL1Jpj9h:1","article_id":"2579811787","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579811787","pubTimestamp":1761822042,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aquestive Therapeutics Inc. has announced that multiple presentations related to its investigational product candidate Anaphylm  sublingual film will be featured at the 2025 American College of Allergy, Asthma and Immunology  Annual Meeting, taking place November 6-10, 2025, in Orlando, FL. The presentations will include an oral session on Phase 1 evaluation of sublingual film pharmacokinetics, pharmacodynamics, safety, and tolerability in at-risk pediatric patients, as well as poster presentations on pharmacokinetics in adult and pediatric subjects and insights from clinician and caregiver surveys regarding unmet needs in anaphylaxis care. The results are scheduled to be presented at the ACAAI Annual Meeting, and abstracts will be made available online beginning November 6, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4007":"制药","AQST":"Aquestive Therapeutics Inc.","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Aquestive Therapeutics在2025年ACAAI会议上强调Anaphylm 1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9,"NDAQ":0.9},"content_text":"Aquestive Therapeutics Highlights Anaphylm Phase 1 Results at 2025 ACAAI Meeting\n    \n\nAquestive Therapeutics Inc. has announced that multiple presentations related to its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, taking place November 6-10, 2025, in Orlando, FL. The presentations will include an oral session on Phase 1 evaluation of sublingual film pharmacokinetics, pharmacodynamics, safety, and tolerability in at-risk pediatric patients, as well as poster presentations on pharmacokinetics in adult and pediatric subjects and insights from clinician and caregiver surveys regarding unmet needs in anaphylaxis care. The results are scheduled to be presented at the ACAAI Annual Meeting, and abstracts will be made available online beginning November 6, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564886-en) on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}